---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-020608"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T12:21:38.943493+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Beam Therapeutics Q4 net income $142.8M; cash $1.2B, runway to 2027

## Summary
- Q4 net income $142.8M ($1.77 basic EPS) vs net loss $38.3M in Q4 2022; full-year net loss $132.5M vs $289.1M loss in 2022.
- Cash, equivalents and marketable securities $1.2B at Dec 31, 2023, expected to fund operations into 2027.
- BEAM-101 in SCD: sentinel cohort dosing and expansion cohort initiation H1 2024; initial clinical data expected H2 2024.
- BEAM-302 for AATD Phase 1 trial initiation on track for H1 2024 pending CTA acceptance; BEAM-301 IND submission H1 2024.
- R&D expenses rose to $140.1M Q4 (vs $86.3M) and $437.4M FY (vs $311.6M); G&A expenses $43.3M Q4 (vs $22.7M).

## SEC filing metadata
- accession: 0000950170-24-020608
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017024020608/0000950170-24-020608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017024020608/beam-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-020608
- JSON: https://secwatch.observer/filing/0000950170-24-020608.json
- Plain text: https://secwatch.observer/filing/0000950170-24-020608.txt

## Key facts
- Earnings Releases
  Beam Therapeutics Inc. reported the year ended December 31, 2023 results: net income net loss attributable to common stockholders was $132.5 million, or $1.72 per share, for the year ended December 31, 202, EPS $1.72 per share.
  - Period: the year ended December 31, 2023
  - Net income: net loss attributable to common stockholders was $132.5 million, or $1.72 per share, for the year ended December 31, 202
  - EPS: $1.72 per share
  - Result: reported results
  source text: net loss attributable to common stockholders was $132.5 million, or $1.72 per share, for the year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000095017024020608/0000950170-24-020608-index.htm
- Earnings Releases
  Beam Therapeutics Inc. reported the fourth quarter of 2023 results: net income Net income attributable to common stockholders was $142.8 million, or $1.77 per basic share and $1.73 per diluted share,, EPS $1.77 per basic share and $1.73 per diluted share.
  - Period: the fourth quarter of 2023
  - Net income: Net income attributable to common stockholders was $142.8 million, or $1.77 per basic share and $1.73 per diluted share,
  - EPS: $1.77 per basic share and $1.73 per diluted share
  - Result: reported results
  source text: Net income attributable to common stockholders was $142.8 million, or $1.77 per basic share and $1.73 per diluted share, for the fourth quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000095017024020608/0000950170-24-020608-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.